Recent Blog Posts

View Post: Social Security, Compassionate Allowances - hadit.com Veterans Forum
22 hours ago
Initial List of Compassionate Allowance Conditions List of Conditions. 1. Acute Leukemia. 2. Adrenal Cancer - with distant metastases or inoperable, unresectable or recurrent. 3. Alexander Disease (ALX) - Neonatal and Infantile ... Frontotemporal Dementia (FTD), Picks Disease -Type A - Adult. 19. Gallbladder Cancer. 20. Gaucher Disease (GD) - Type 2. 21. Glioblastoma Multiforme (Brain Tumor). 22. Head and Neck Cancers - with distant metastasis or inoperable or uresectable ...
View Blog: HadIt.com VA Claims Research - http://www.hadit.com/forums/index.php

---

View Post: Velaglucerase alfa Gaucher disease drug by Shire may get speedier ...
5 Nov 2009 by pillscribe  
Velaglucerase alfa, an enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease, has been granted priority review by the United States Food and Drug Administration, maker of the drug Shire plc announced. ...
View Blog: DWS Pill Scribe - http://www.dancewithshadows.com/pillscribe/

---

View Post: FDA Grants Priority Review for Shire's velaglucerase alfa for Type ...
4 Nov 2009
Gaucher disease has classically been categorized into 3 clinical types. Type 1 is the most common; it is distinguished from Type 2 and Type 3 by the lack of central nervous system involvement. Type 1 Gaucher disease is characterized by ...
View Blog: Drugs.com - New Drug Applications - http://www.drugs.com/new-drug-applications.html

---

View Post: FDA Grants Priority Review for Shire's velaglucerase alfa for Type ...
3 Nov 2009 by Prne  
Gaucher disease is the most prevalent lysosomal storage disorder, with an incidence of about 1 in 20000 live births. Gaucher disease has classically been categorized into 3 clinical types. Type 1 is the most common; it is distinguished ...
View Blog: PR Hub - http://blog.taragana.com/pr/

---

View Post: FDA Grants Priority Review for Shire's velaglucerase alfa for Type ...
3 Nov 2009
FDA Grants Priority Review for Shire's velaglucerase alfa for Type 1 Gaucher Disease- FDA Issued Action Date of February 28, 2010 Under the Prescription Drug User Free Act (PDUFA)PR NewswireCAMBRIDGE, Massachusetts, November 4CAMBRIDGE, ...
View Blog: Pharmaceutical Events (November-2009) - http://www.pharmiweb.com/

---

View Post: Velaglucerase alfa for Type 1 Gaucher disease
5 Nov 2009
The United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher ...
View Blog: Current R&D of Pharmaceutical - http://www.cradop.com/component/content/frontpage.html

---

View Post: Gaucher's disease at a glance
YES Disease
25 Oct 2009 by morello   ...
View Blog: http://www.yesdisease.com/

---